JPRN-jRCT2031210174招募中2 期
An Open label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the neoadjuvant / adjuvant treatment for Patients with Gastric Cancer
Kawazoe Akihito0 个研究点目标入组 43 人开始时间: 2021年6月29日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Have gastric and gastroesophageal junction adenocarcinoma
- •2)Untreated and cT2-4 and/or cN+ without evidence of metastatic disease
- •3)Patients at least 20 years of age on the day of providing consent.
- •4)Patients with a performance status of 0 or 1 on the Eastern Cooperative Oncology Group.
- •5)Patients with adequate organ function at the time of enrollment as defined below:
- •Neutrophil count >=1,500mm3
- •Platelet count >= 100,000/mm3
- •Hemoglobin (Hb) >= 9.0 g/dL,
- •Total bilirubin =<1.5 mg/dL
- •AST (GOT) and ALT (GPT) =< 100 IU/L
- •Creatinine =< 1.5 mg/dL
- •Urinary protein : It satisfies one of the following (if any of the inspection criteria are satisfied, other examination may not be carried out)
- •(i) urinary protein (test paper method) is 2+ or less
- •(ii) Urine Protein Creatinine (UPC) ratio < 3.5
- •(iii) 24-hour urine protein was measured, urinary protein =< 3,500 mg
- •International normalized ratio (INR) =< 1.5
- •6)Patients who not received a blood transfusion within 14 days of registration.
- •7)Patients have recovered adverse events associated with radiation and surgical operation as pretreatment to Grade 1 or less or baseline or less with CTCAE v5.0 excluding stable symptoms. However, adverse events with stable symptoms even with Grade 2 or higher excluded.
- •8)Female of childbearing potential who are negative in a pregnancy test within 14 days before enrollment. Both male and female patients should agree to use an adequate method of contraception (total abstinence or use of a male condom plus partner use of contraceptive method [an intrauterine device or hormone releasing system, an contraceptive implant and an oral contraceptive]) starting with the first dose of study therapy through 120 days after the last dose of study therapy. Duration will be determined when the subject is assigned to treatment.
- •9)Patients capable of taking oral medication.
- •10)Patients who provided written informed consent to be subjects in this study.
排除标准
- •1)Patients who have undergone surgical treatment and radiotherapy with in 2 weeks before enrollment.
- •2)Patients with hypertension that is difficult to control (systolic blood pressure >= 140 mmHg and diastolic blood pressure >= 90 mmHg) despite treatment with several hypotensive agents.
- •3)Patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrollment.
- •4)Patients with a history of New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction.
- •5)Patients have an additional active malignancy (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 24 months.
- •6)Patients have severe (hospitalization required) complications (intenstinal palsy, intestinal obstruction, pulmonary fibrosis, diabetes difficult to control, heart failure, myocardial infarction, unstable angina, renal failure, liver failure, mental disease, cerebrovascular disease etc).
- •7)Patients with a history of a gastrointestinal perforation and /or gastrointestinal fistula within 6 months before enrollment.
- •8)Is infected with active hepatitis B (defined as HBs antigen positive) or hepatitis C.
- •9)Patients with a history of human immunodeficiency virus (HIV).
- •10)Patients with a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
- •11)Patients who are administered live vaccines < 30 days before the initiation of treatment with the investigational drug.
- •12)Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease.
- •13)Patients who require systemic corticosteroids (excluding temporary usage for tests, prophylactic administration for allergic reactions, or to alleviate swelling associated with radiotherapy) or immunosuppressants, or who have received such a therapy < 14 days before enrollment.
- •14)Patients have serious non-healing wound, ulcer, or bone fracture.
- •15)Females who are pregnant or breastfeeding.
- •16)Patients have no intention to comply with the protocol or cannot comply.
- •17)Patients were judged unsuitable as subject of this study by investigator.
研究者
相似试验
未知
2 期
A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult SubjectsPrevention of Influenza infectionJPRN-jRCT2080223134TAKEDA PHARMACEUTICAL COMPANY LTD.55
进行中（未招募）
1 期
A study to see if Aceneuramic Acid is safe in treating people with GNE Myopathy (GNEM) patients (a rare muscle disease also known as Hereditary Inclusion Body Myopathy (HIBM)) with severe ambulatory impairment.EUCTR2015-004553-41-BGltragenyx Pharmaceutical Inc.45
进行中（未招募）
1 期
An international study to assess the safety and efficacy of a combination of new investigational drugs in hepatitis C virus infected patients with advanced liver disease or require treatment after kidney transplantation.Chronic Genotype 1 and Genotype 4 Hepatitis C Virus InfectionMedDRA version: 18.0Level: LLTClassification code 10019751Term: Hepatitis C virusSystem Organ Class: 100000004848EUCTR2014-002121-35-DEGilead Sciences, Inc.150
进行中（未招募）
1 期
An international study to assess the safety and efficacy of a combination of new investigational drugs in hepatitis C virus infected patients with advanced liver disease or require treatment after kidney transplantation.Chronic Genotype 1 and Genotype 4 Hepatitis C Virus InfectionMedDRA version: 17.0Level: LLTClassification code 10019751Term: Hepatitis C virusSystem Organ Class: 100000004848EUCTR2014-002121-35-ITGilead Sciences, Inc.150
进行中（未招募）
1 期
An international study to assess the safety and efficacy of a combination of new investigational drugs in hepatitis C virus infected patients with advanced liver disease or require treatment after kidney transplantation.Chronic Genotype 1 and Genotype 4 Hepatitis C Virus InfectionMedDRA version: 18.1Level: LLTClassification code 10019751Term: Hepatitis C virusSystem Organ Class: 100000004848EUCTR2014-002121-35-ATGilead Sciences, Inc.150